Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Increases By 400.0%

enGene Holdings Inc. (NASDAQ:ENGNW) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 16,000 shares, a growth of 400.0% from the February 29th total of 3,200 shares. Based on an average trading volume of 39,600 shares, the days-to-cover ratio is presently 0.4 days.

enGene Stock Down 0.8 %

NASDAQ ENGNW opened at $5.20 on Friday. enGene has a 52-week low of $0.39 and a 52-week high of $6.50. The stock’s fifty day moving average is $3.17.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.